Biolargo Stock Price To Sales
| BLGO Stock | USD 0.20 0.02 11.11% |
BioLargo fundamentals help investors to digest information that contributes to BioLargo's financial success or failures. It also enables traders to predict the movement of BioLargo OTC Stock. The fundamental analysis module provides a way to measure BioLargo's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioLargo otc stock.
BioLargo |
BioLargo OTC Stock Price To Sales Analysis
BioLargo's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current BioLargo Price To Sales | 11.52 X |
Most of BioLargo's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioLargo is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, BioLargo has a Price To Sales of 11.5249 times. This is 56.54% lower than that of the Chemicals sector and notably higher than that of the Materials industry. This indicator is about the same for all United States stocks average (which is currently at 11.42).
BioLargo Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioLargo's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of BioLargo could also be used in its relative valuation, which is a method of valuing BioLargo by comparing valuation metrics of similar companies.BioLargo is currently under evaluation in price to sales category among its peers.
BioLargo Fundamentals
| Return On Equity | -3.63 | |||
| Return On Asset | -0.69 | |||
| Profit Margin | (1.29) % | |||
| Operating Margin | (1.16) % | |||
| Current Valuation | 52.87 M | |||
| Shares Outstanding | 275.42 M | |||
| Shares Owned By Insiders | 14.70 % | |||
| Shares Owned By Institutions | 0.04 % | |||
| Price To Earning | (4.54) X | |||
| Price To Book | 10.61 X | |||
| Price To Sales | 11.52 X | |||
| Revenue | 2.53 M | |||
| Gross Profit | 1.1 M | |||
| EBITDA | (6.64 M) | |||
| Net Income | (7.08 M) | |||
| Cash And Equivalents | 1.23 M | |||
| Total Debt | 367 K | |||
| Debt To Equity | 0.72 % | |||
| Current Ratio | 1.82 X | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | (3.94 M) | |||
| Earnings Per Share | (0.03) X | |||
| Target Price | 0.29 | |||
| Number Of Employees | 31 | |||
| Beta | -0.0345 | |||
| Market Capitalization | 64.59 M | |||
| Total Asset | 3.02 M | |||
| Retained Earnings | (89.68 M) | |||
| Working Capital | 1.04 M | |||
| Current Asset | 1.87 M | |||
| Current Liabilities | 831 K | |||
| Z Score | 57.8 | |||
| Net Asset | 3.02 M |
About BioLargo Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioLargo's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioLargo using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioLargo based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Other Information on Investing in BioLargo OTC Stock
BioLargo financial ratios help investors to determine whether BioLargo OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioLargo with respect to the benefits of owning BioLargo security.